An estimated 65,000 New Zealanders are prescribed medication for Attention Deficit Hyperactivity Disorder - or ADHD.
Pharmac is planning to fund a new brand of ADHD medication from the first of December, and is currently consulting on the change.
If approved, a generic equivalent to the commonly prescribed Concerta brand will be available.
The move is supported by the advocacy group ADHD New Zealand, and comes amid ongoing global supply issues for ADHD medication, and in anticipation of new regulations which from February next year will allow more health professionals - including GPs and nurse practitioners - to prescribe ADHD medicines.
Kathryn speaks with Pharmac's Chief Medical Officer Dr David Hughes and Sarah Hogan, who is on the board of ADHD New Zealand.
